Home/ Stocks/ XNCR

Xencor, Inc.

XNCR XNAS

$12.86 +0.55 (+4.47%) ▲ 15-min delayed

Open

$12.22

High

$13.15

Low

$12.00

Volume

899.5K

Market Cap

$953.46M

About Xencor, Inc.

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 260 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$4.52M	$-128,916,000	$-1.71
FY 2025	$125.58M	$-92,137,000	$-1.24
Q3 2025	$21.00M	$-6,027,000	$-0.08
Q2 2025	$43.61M	$-30,825,000	$-0.41

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for XNCR yet. Check out our latest market news or earnings calendar.

Get XNCR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Xencor, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.